Identification of new therapiutic molecules for CRPC by using library screening methods

2015 Fiscal Year Final Research Report

• Project/Area Number: 26670700
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Urology
• Research Institution: Kyoto University
• Principal Investigator: Nakamura Eijiro 京都大学, 医学(系)研究科(研究院), 准教授 (90293878)
• Co-Investigator(Kenkyū-buntansha): MUROFUSHI YOSHITERU 京都大学, 医学研究科, 研究員 (50448578)
• Co-Investigator(Renkei-kenkyūsha): INOUE TAKAHIRO 京都大学, 医学研究科, 講師 (80511881)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Keywords: CRPC / Androgen

Outline of Final Research Achievements

It is important to establish new therapeutic strategy for prostate cancer since the number of patients is most rapidly increased among all types of cancer disease in these 20 years. Although the androgen ablation therapy is performed as a standard therapy for patients with advanced disease, however, cancer cell finally acquire resistance in most cases, so called Castration Resistant Prostate Cancer (CRPC).
We have succeeded in establishing several CRPC cell lines expressing abundant PSA and AR by using LNCaP cells and shRNA library. We are planning to clarify the mechanisms of androgen-independent growth of prostate cancer cells through the analysis of these cells.

Free Research Field

前立腺癌